Some clinical studies demonstrated that PD-L1 expression on tumor cells or in the tumor microenvironment positively correlates with the response rate of anti-PD-1/PD-L1 therapy, indicating that PD-L1 may serve as a potential selection marker for patient stratification [5]. The gene discussed is PDCD1; the disease is neoplasm.